SG10201709016RA - Compositions for continuous administration of dopa decarboxylase inhibitors - Google Patents
Compositions for continuous administration of dopa decarboxylase inhibitorsInfo
- Publication number
- SG10201709016RA SG10201709016RA SG10201709016RA SG10201709016RA SG10201709016RA SG 10201709016R A SG10201709016R A SG 10201709016RA SG 10201709016R A SG10201709016R A SG 10201709016RA SG 10201709016R A SG10201709016R A SG 10201709016RA SG 10201709016R A SG10201709016R A SG 10201709016RA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- continuous administration
- dopa decarboxylase
- decarboxylase inhibitors
- inhibitors
- Prior art date
Links
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17951109P | 2009-05-19 | 2009-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201709016RA true SG10201709016RA (en) | 2017-11-29 |
Family
ID=42320738
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011085297A SG176159A1 (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
| SG10201505101VA SG10201505101VA (en) | 2009-05-19 | 2010-05-17 | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
| SG10201709016RA SG10201709016RA (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011085297A SG176159A1 (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
| SG10201505101VA SG10201505101VA (en) | 2009-05-19 | 2010-05-17 | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8193243B2 (hr) |
| EP (3) | EP2432454B1 (hr) |
| JP (3) | JP5643297B2 (hr) |
| KR (2) | KR101709904B1 (hr) |
| CN (2) | CN102438587B (hr) |
| AR (3) | AR078413A1 (hr) |
| AU (1) | AU2010250766B2 (hr) |
| BR (1) | BRPI1011031B8 (hr) |
| CA (1) | CA2761624C (hr) |
| CL (1) | CL2011002895A1 (hr) |
| CY (1) | CY1119495T1 (hr) |
| DK (2) | DK3192500T3 (hr) |
| ES (2) | ES2840748T3 (hr) |
| HR (2) | HRP20170805T1 (hr) |
| HU (2) | HUE033388T2 (hr) |
| IL (1) | IL216383A (hr) |
| LT (1) | LT2432454T (hr) |
| MX (2) | MX2011012315A (hr) |
| NZ (1) | NZ596963A (hr) |
| PL (2) | PL3192500T3 (hr) |
| PT (2) | PT2432454T (hr) |
| RU (3) | RU2678839C2 (hr) |
| SG (3) | SG176159A1 (hr) |
| SI (1) | SI2432454T1 (hr) |
| WO (1) | WO2010134074A1 (hr) |
| ZA (1) | ZA201109037B (hr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN192600B (hr) * | 1996-10-18 | 2004-05-08 | Hoechst Celanese Corp | |
| EP2432454B1 (en) | 2009-05-19 | 2017-03-01 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| DK3326615T3 (da) * | 2010-11-15 | 2020-03-09 | Neuroderm Ltd | Kontinuerlig indgivelse af l-dopa-, dopa- decarboxylase-inhibitorer, catechol-o-methyltransferaseinhibitorer og sammensætninger til samme |
| CA2875446A1 (en) | 2012-06-05 | 2013-12-12 | Neuroderm Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| CN103845318A (zh) * | 2012-12-07 | 2014-06-11 | 天津市汉康医药生物技术有限公司 | 恩他卡朋分散片 |
| RU2677278C2 (ru) | 2013-03-13 | 2019-01-16 | Неуродерм Лтд | Способ лечения болезни паркинсона |
| AU2014346855B2 (en) * | 2013-11-05 | 2019-07-18 | Synagile Corporation | Devices and methods for continuous drug delivery via the mouth |
| BR112016021034A8 (pt) * | 2014-03-13 | 2021-06-29 | Neuroderm Ltd | composição farmacêutica, uso da mesma e kit |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PT3782617T (pt) * | 2014-09-04 | 2024-02-29 | Lobsor Pharmaceuticals Ab | Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona |
| BR112017008198B1 (pt) | 2014-10-21 | 2021-02-09 | Abbvie Inc | combinação farmacêutica compreendendo pró-fármacos de carbidopa e l-dopa e uso da mesma para a preparação de uma composição farmacêutica para tratar doença de parkinson |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| AU2016358511A1 (en) | 2015-11-24 | 2018-06-21 | Neuroderm Ltd. | Pharmaceutical compositions comprising levodopa amide and uses thereof |
| US10874629B2 (en) | 2016-04-11 | 2020-12-29 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| US10064834B2 (en) | 2016-05-09 | 2018-09-04 | Texas Tech University System | Carbidopa for the treatment of cancer |
| EA201992685A1 (ru) * | 2017-06-05 | 2020-06-05 | Дизлин Фармасьютикалз Аб | Раствор леводопы для инфузий |
| US20230123806A1 (en) * | 2017-07-07 | 2023-04-20 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
| JP2021517128A (ja) * | 2018-03-29 | 2021-07-15 | アヴィオン ファーマシューティカルズ、リミティッド ライアビリティ カンパニー | レボドパ分割用量組成物および使用 |
| US20220226269A1 (en) * | 2019-06-12 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| WO2023126945A1 (en) * | 2022-01-03 | 2023-07-06 | Neuroderm, Ltd. | Methods and compositions for treating parkinson's disease |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769424A (en) * | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE3779500T2 (de) | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| WO1992007561A1 (fr) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Preparation d'un gel anti-inflammatoire et analgesique |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US6245917B1 (en) | 1998-03-20 | 2001-06-12 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| PT1077692E (pt) | 1998-05-15 | 2004-12-31 | Warner Lambert Co | Preparacoes farmaceuticas estabilizadas de derivados do acido aminobutirico e processos para a sua preparacao |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2000054773A1 (en) | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| US6916813B2 (en) | 2001-12-10 | 2005-07-12 | Bristol-Myers Squibb Co. | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
| EA200401334A1 (ru) | 2002-04-11 | 2005-04-28 | Ранбакси Лабораторис Лимитед | Фармацевтические композиции карбидопы и леводопы с контролируемым высвобождением |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| AU2003301414B8 (en) | 2002-10-10 | 2010-06-17 | Morphochem Aktiengesellschaft Fur Kombinatorische Chemie | Novel compounds with antibacterial activity |
| RU2426590C2 (ru) | 2003-07-18 | 2011-08-20 | Бакстер Интернэшнл Инк. | Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| ATE495739T1 (de) * | 2003-08-29 | 2011-02-15 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| CN1901879A (zh) * | 2003-10-31 | 2007-01-24 | 阿尔扎公司 | 左旋多巴和卡比多巴的给药 |
| AU2004285532A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Administration of levodopa and carbidopa |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| PL1797109T3 (pl) | 2004-09-09 | 2016-11-30 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania | |
| WO2006037061A2 (en) | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| WO2006043532A1 (ja) * | 2004-10-19 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | パーキンソン病治療剤 |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0711882A2 (pt) | 2006-05-31 | 2012-01-10 | Solvay Pharm Gmbh | administração intestinal de longo termo durante 24 horas de levodopa/carbidopa |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| WO2008124330A2 (en) * | 2007-04-06 | 2008-10-16 | Transform Pharmaceuticals, Inc. | Systems and methods for delivering a fluid drug |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| EP2432454B1 (en) | 2009-05-19 | 2017-03-01 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| ES2673219T3 (es) | 2010-11-15 | 2018-06-20 | Neuroderm Ltd | Composición para la entrega transdérmica de agentes activos |
| DK3326615T3 (da) | 2010-11-15 | 2020-03-09 | Neuroderm Ltd | Kontinuerlig indgivelse af l-dopa-, dopa- decarboxylase-inhibitorer, catechol-o-methyltransferaseinhibitorer og sammensætninger til samme |
| WO2012079072A2 (en) | 2010-12-10 | 2012-06-14 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| RU2677278C2 (ru) | 2013-03-13 | 2019-01-16 | Неуродерм Лтд | Способ лечения болезни паркинсона |
| BR112016021034A8 (pt) | 2014-03-13 | 2021-06-29 | Neuroderm Ltd | composição farmacêutica, uso da mesma e kit |
-
2010
- 2010-05-17 EP EP10725880.8A patent/EP2432454B1/en active Active
- 2010-05-17 KR KR1020167019114A patent/KR101709904B1/ko active IP Right Grant
- 2010-05-17 MX MX2011012315A patent/MX2011012315A/es active IP Right Grant
- 2010-05-17 SG SG2011085297A patent/SG176159A1/en unknown
- 2010-05-17 RU RU2015115064A patent/RU2678839C2/ru active
- 2010-05-17 MX MX2015001674A patent/MX364974B/es unknown
- 2010-05-17 SG SG10201505101VA patent/SG10201505101VA/en unknown
- 2010-05-17 CA CA2761624A patent/CA2761624C/en active Active
- 2010-05-17 JP JP2012511409A patent/JP5643297B2/ja active Active
- 2010-05-17 SI SI201031466T patent/SI2432454T1/sl unknown
- 2010-05-17 PL PL17158360T patent/PL3192500T3/pl unknown
- 2010-05-17 US US12/781,357 patent/US8193243B2/en active Active
- 2010-05-17 KR KR1020117030315A patent/KR101641401B1/ko active IP Right Grant
- 2010-05-17 PT PT107258808T patent/PT2432454T/pt unknown
- 2010-05-17 PT PT171583602T patent/PT3192500T/pt unknown
- 2010-05-17 LT LTEP10725880.8T patent/LT2432454T/lt unknown
- 2010-05-17 BR BRPI1011031A patent/BRPI1011031B8/pt active IP Right Grant
- 2010-05-17 PL PL10725880T patent/PL2432454T3/pl unknown
- 2010-05-17 EP EP17158360.2A patent/EP3192500B1/en active Active
- 2010-05-17 DK DK17158360.2T patent/DK3192500T3/da active
- 2010-05-17 SG SG10201709016RA patent/SG10201709016RA/en unknown
- 2010-05-17 WO PCT/IL2010/000400 patent/WO2010134074A1/en active Application Filing
- 2010-05-17 RU RU2011149976/15A patent/RU2559083C9/ru active
- 2010-05-17 NZ NZ596963A patent/NZ596963A/en not_active IP Right Cessation
- 2010-05-17 HU HUE10725880A patent/HUE033388T2/en unknown
- 2010-05-17 ES ES17158360T patent/ES2840748T3/es active Active
- 2010-05-17 EP EP20197759.2A patent/EP3777839A1/en active Pending
- 2010-05-17 AU AU2010250766A patent/AU2010250766B2/en active Active
- 2010-05-17 DK DK10725880.8T patent/DK2432454T3/en active
- 2010-05-17 HU HUE17158360A patent/HUE052685T2/hu unknown
- 2010-05-17 ES ES10725880.8T patent/ES2627655T3/es active Active
- 2010-05-17 CN CN201080022208.3A patent/CN102438587B/zh active Active
- 2010-05-17 CN CN201410800432.0A patent/CN104546700B/zh active Active
- 2010-05-19 AR ARP100101735A patent/AR078413A1/es not_active Application Discontinuation
- 2010-07-14 US US12/836,130 patent/US7863336B2/en active Active
- 2010-12-07 US US12/961,534 patent/US9101663B2/en active Active
-
2011
- 2011-11-15 IL IL216383A patent/IL216383A/en active IP Right Grant
- 2011-11-17 CL CL2011002895A patent/CL2011002895A1/es unknown
- 2011-12-08 ZA ZA2011/09037A patent/ZA201109037B/en unknown
-
2014
- 2014-05-13 US US14/276,235 patent/US9040590B2/en active Active
- 2014-05-13 US US14/276,211 patent/US9040589B2/en active Active
- 2014-10-30 JP JP2014221786A patent/JP5921002B2/ja active Active
-
2015
- 2015-07-01 US US14/789,214 patent/US9993451B2/en active Active
-
2016
- 2016-04-08 JP JP2016078121A patent/JP6157678B2/ja active Active
-
2017
- 2017-05-30 HR HRP20170805TT patent/HRP20170805T1/hr unknown
- 2017-05-31 CY CY20171100573T patent/CY1119495T1/el unknown
-
2018
- 2018-05-30 US US15/992,979 patent/US20190125708A1/en not_active Abandoned
-
2019
- 2019-01-16 RU RU2019101159A patent/RU2019101159A/ru unknown
- 2019-03-28 AR ARP190100805A patent/AR117412A2/es unknown
- 2019-12-23 AR ARP190103847A patent/AR117502A2/es unknown
-
2020
- 2020-04-30 US US16/863,459 patent/US20210077442A1/en not_active Abandoned
- 2020-12-21 HR HRP20202038TT patent/HRP20202038T1/hr unknown
-
2022
- 2022-11-11 US US17/985,556 patent/US20230321019A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201109037B (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
| IL263954A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyltransferase inhibitors, and pharmaceutical preparations that include them | |
| HK1162352A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| HK1156306A1 (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4- | |
| EP2470019A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS | |
| HK1167999A1 (en) | Lysosomotropic inhibitors of acid ceramidase | |
| PL2642993T3 (pl) | Kompozycje rotygotyny lub farmaceutycznie dopuszczalnych soli rotygotyny | |
| HU0900072D0 (en) | Transdermal pharmaceutical compositions | |
| EP2616053A4 (en) | PHARMACEUTICAL COMPOSITIONS FROM CURCUMIN | |
| ZA201203012B (en) | Solid pharmaceutical compositions containing an intergrase inhibitor | |
| ZA201107122B (en) | Stable pharmaceutical compositions of diclofenac | |
| EP2152232A4 (en) | METHOD AND COMPOSITIONS FOR OXYBUTYNINE ADMINISTRATION | |
| EP2424533A4 (en) | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS | |
| ZA201300009B (en) | Oral formulation of kinase inhibitors | |
| PT2411376E (pt) | Inibidores de nf-kb | |
| EP2543373A4 (en) | PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND | |
| IL215486A0 (en) | Compositions of cholinesterase inhibitors | |
| EP2484367A4 (en) | MEANS OF PREVENTING UNWANTED SIDE EFFECTS OF A CARCINUTATIVE MEDIUM | |
| IL226239A0 (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyl inhibitors | |
| GB0803895D0 (en) | Inhibitors of glyoxalase |